The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame during the COVID-19 pandemic. The beauty of mRNA technology is that it opens the door to a more personalized and effective treatment as messenger RNA instructs the patient's cells how to combat diseases like cancer.
Moderna Inc (NASDAQ:MRNA) and Merck & Co (NYSE:MRK) joined forces to advance cancer treatment with an experimental mRNA vaccine, used in combination with Merck's blockbuster immunotherapy drug Keytruda. With promising mid-stage trial results in the battle against melanoma, the duo is also conducting a...
Login or create a forever free account to read this news
Sign up/Log in